Evolution of Live-Attenuated HIV Vaccines - Safety concerns remain for developing replicating vectors based on the pathogen human immunodeficiency virus type 1. - BioPharm International


Evolution of Live-Attenuated HIV Vaccines
Safety concerns remain for developing replicating vectors based on the pathogen human immunodeficiency virus type 1.

BioPharm International Supplements
Volume 24, pp. s4-s8


1. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010;28(6):573–9.

2. Johnson RP, Desrosiers RC. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol. 1998;10(4):436–43.

3. Mills J, Desrosiers R, Rud E, Almond N. Live attenuated HIV vaccines: proposal for further research and development. AIDS Res. Hum Retroviruses 2000;16:1453–61.

4. Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis. 2004;17(1):17–26.

5. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol. 2006;7(1):19–23.

6. Baba TW, Jeong YS, Penninck D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 1995;267:1820–5.

7. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med. 1999;5:194–203.

8. Chakrabarti LA, Metzner KJ, Ivanovic T, Cheng H, Louis-Virelizier J, Connor RI, Cheng-Mayer C. A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J Virol. 2003;77(2):1245–56.

9. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol. 1995;69:5117–23.

10. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, Anderson DC, O'Neil S, Ruprecht RM. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS. 2003;24:17(2):157–66.

11. Churchill MJ, Rhodes DI, Learmont JC, Sullivan JS, Wesselingh SL, Cooke IR, Deacon NJ, Gorry PR. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol. 2006;80(2):1047–52.

12. Berkhout B, Verhoef K, van Wamel JLB, Back B. Genetic instability of live-attenuated HIV-1 vaccine strains. J Virol. 1999;73:1138–45.

13. Berkhout B, Paxton WA. HIV vaccine: it may take two to tango, but no party time yet. Retrovirol. 2009;6:88.

14. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, van Rompay KK, et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 1994;68:7021–9.

15. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immuodeficiency virus. J Virol. 1996;70:3724–33.

16. Lifson JD, Rossio JL, Piatak M Jr., Parks T, Li L, Kiser R, et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol. 2001;75(21):10187–99.

17. Evans DT, Bricker JE, Desrosiers RC. A novel approach for producing lentiviruses that are limited to a single cycle of infection. J Virol. 2004;78(21):11715–25.

18. Evans DT, Bricker JE, Sanford HB, Lang S, Carville A, Richardson BA, et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol. 2005;79(12):7707–20.

19. Falkensammer B, Rubner B, Hiltgartner A, Wilflingseder D, Stahl HC, Kuate S, et al. Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors. Retrovirol. 2009;6:60.

20. Kuate S, Stahl-Hennig C, ten HP, Heeney J, Uberla K. Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines. Virol. 2003;313(2):653–62.

blog comments powered by Disqus



FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here